Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Gilead Sciences Inc. lifted its full-year outlook after strong HIV drug sales in the second quarter helped revenue and ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV ...

Amid the questions about the Yeztugo rollout, Gilead’s second quarter performance offered some reassurance about the ...

Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black women-serving organizations in the U.S. since 2010, with $28 million granted to ...